Aldeyra Therapeutics has entered into an exclusive option agreement with AbbVie for license to develop, manufacture and commercialize reproxalap, the company announced in a press release.
According to Aldeyra, reproxalap is a reactive aldehyde species modulator for potential treatment of dry eye disease, for which it is currently under FDA review, as well as allergic conjunctivitis.
Under the terms of the option agreement, AbbVie may acquire a co-exclusive license to develop, manufacture and commercialize reproxalap in the U.S., as well as exclusive license for the product outside the U.S., the